Phase I Study of Oral Yeast Beta-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Beta glucan (Primary) ; Monoclonal antibody 3F8 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 08 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
- 08 Mar 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 07 Mar 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.